Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.160
0.00 (0.00%)
Apr 22, 2025, 11:11 AM EDT - Market open
Chemomab Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Strong Buy
Price Target
$9.00
Upside
+675.86%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +503.45% | Feb 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $13 → $11 | Buy | Reiterates | $13 → $11 | +848.28% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +244.83% | May 13, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +417.24% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 8, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +503.45% | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +503.45% | Oct 6, 2023 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +503.45% | Apr 18, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +1,624.14% | Mar 10, 2022 |
| Aegis Capital | Aegis Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,486.21% | Dec 7, 2021 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $45 | Buy | Initiates | $45 | +3,779.31% | May 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $42 | Buy | Initiates | $42 | +3,520.69% | May 7, 2021 |